Clinical Trials - May 18, 2022
EpiEndo completes Phase I study
EpiEndo Pharmaceuticals has completed its Phase I First Time in Human (FTIH) study with EP395 in healthy subjects. EP395 is the first of EpiEndo’s orally available, non-antibiotic macrolides or ‘Barriolides’ to enter clinical development and will be targeting chronic obstructive pulmonary disease (COPD). Read more: A Nordic star on a global mission The study was […]
In a new job - March 25, 2022
EpiEndo appoints new Chief Financial Officer
EpiEndo Pharmaceuticals has announced the appointment of Stefan Petursson as Chief Financial Officer (CFO). Stefan Petursson is taking over the role of CFO from Finnur Einarsson who will now focus on his role as Chief Operations Officer (COO). “I am delighted to welcome Stefan to EpiEndo as CFO,” commented Maria Bech, CEO of EpiEndo Pharmaceuticals. […]
Business article - March 9, 2022
A Nordic star on a global mission
EpiEndo Pharmaceuticals is on the rise. The company has recently secured next phase financing and been awarded several prestigious awards, and is on course to potentially change the treatment paradigm for chronic obstructive pulmonary disease. At the Swedish-American Life Science Summit (SALSS) 2021, the Icelandic clinical stage pharma company EpiEndo received the SALSS Rising Star […]
